Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Relay Therapeutics (RLAY) Research & Development (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Research & Development for 6 consecutive years, with $55.4 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 18.6% to $55.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $261.4 million through Dec 2025, down 18.08% year-over-year, with the annual reading at $261.4 million for FY2025, 18.08% down from the prior year.
  • Research & Development for Q4 2025 was $55.4 million at Relay Therapeutics, down from $68.3 million in the prior quarter.
  • The five-year high for Research & Development was $92.0 million in Q2 2024, with the low at $30.6 million in Q1 2021.
  • Average Research & Development over 5 years is $66.5 million, with a median of $67.7 million recorded in 2022.
  • The sharpest move saw Research & Development skyrocketed 108.38% in 2021, then tumbled 30.54% in 2025.
  • Over 5 years, Research & Development stood at $51.9 million in 2021, then grew by 29.61% to $67.3 million in 2022, then grew by 15.19% to $77.5 million in 2023, then decreased by 12.16% to $68.1 million in 2024, then dropped by 18.6% to $55.4 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $55.4 million, $68.3 million, and $63.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.